Favipiravir(6-Fluoro-3-hydroxypyrazine-2-carboxamide), a purine nucleic acid analog thathas been developed by Toyama Chemical in Japan for a treatment of viralinfections including influenza.3 This has recently been evaluated and was foundto be a promising choice in management of COVID-19. It works by inhibiting RNAdependent RNA polymerase (RdRp) enzyme, a key enzyme impeding replication ofRNA viruses.